Sofinnova Venture Partners VIII, L.P. → Aclaris Therapeutics, Inc. ACRS

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 15/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: +0.0%

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

1 transaction

0 buys · 1 sales · 0 awards/exercises

Issuer Cluster

5 13D/G filings on this issuer

4 other filings besides this one

Filer Track Record

7 filings by this filer

6 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 2.95

15,027,284 shares short · -17.4% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $262K

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-04-23	Leonard Braden Michael	10%+ owner	Sale	300,000	$4.53	$1.36M

Other 13D/G Filings on Aclaris Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-09-21	SCHEDULE 13G	Frazier Life Sciences Public Fund, L.P.	—	—	view →
2019-12-19	SC	Arkin Moshe	—	—	view →
2019-11-21	SC	Arkin Moshe	—	—	view →
2019-02-14	SC	VIVO VENTURES VII, LLC	—	—	view →

Other Filings by Sofinnova Venture Partners VIII, L.P.

Filed	Form	Issuer	Stake	Shares
2025-02-25	SCHEDULE	NuCana plc NCNA	10.00%	51,030	view →
2022-02-28	SC	ObsEva SA	—	—	view →
2022-02-28	SC	NuCana plc NCNA	—	—	view →
2021-03-04	SC	ObsEva SA	—	—	view →
2019-02-12	SC	Natera, Inc. NTRA	—	—	view →
2018-02-14	SC	SYNLOGIC, INC. SYBX	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →